File downloaded on 2026-11-26
Source URL: https://medicines.health.europa.eu/veterinary/en/600000017442

Nextmune concentrate and solvent for suspension for injection for chickens

Authorised

- Infectious bursal disease virus, strain Winterfield 2512 (intermediate plus), Live

Product identification

Medicine name:
Nextmune concentrate and solvent for suspension for injection for chickens

Active substance:
Infectious bursal disease virus, strain Winterfield 2512 (intermediate plus), Live

Target species:
Chicken (broiler)
Chicken (embryonated eggs)

Route of administration:
Subcutaneous use
In ovo

Product details

Active substance and strength:
Infectious bursal disease virus, strain Winterfield 2512 (intermediate plus), Live

2.70 log 10 50% embryo infective dose / 1.00 Dose

Pharmaceutical form:
Concentrate and solvent for suspension for injection

Withdrawal period by route of administration:
Subcutaneous use:

- **Chicken (broiler)**
  - Meat and offal. 0 day

In ovo:

- **Chicken (embryonated eggs)**
  - Meat and offal. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI01AD09

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Germany

Available in:
Germany

Package description:
Available only in German
Available only in German
Available only in German
Available only in German
Available only in German
Available only in German
Available only in German

Available only in German
Available only in German
Available only in German

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Ceva Tiergesundheit GmbH

Marketing authorisation date:
6/07/2020

Manufacturing sites for batch release:
Ceva-Phylaxia Zrt.

Responsible authority:
Paul-Ehrlich-Institut

Authorisation number:
PEI.V.11992.01.1

Date of authorisation status change:
6/07/2020

Reference member state:
Spain

Procedure number:
ES/V/0337/001

Concerned member states:
Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia France Germany Greece Hungary Ireland Italy Latvia Lithuania Netherlands Poland

Portugal Romania Slovakia Slovenia United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Labelling

Combined File of all Documents

English (PDF)
Published on: 13/03/2026
Download